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Introduction
Glioblastoma multiforme (GBM) is the most common and 
aggressive type of brain tumor with the median survival of 
14.6 months for newly diagnosed patients.1 Considering that 
the median age of onset is 64 years, it is a sobering that 
the 5-year survival rate is reported to be under 5% among 
patients of 65 years of age or older.2 The current standard 
therapy for newly diagnosed glioma patients consists of 
maximum safe surgical resection of tumor mass followed by 
concomitant or sequential radiation and chemotherapy with 
temozolomide.3 Despite this aggressive multimodal treat-
ment, the prognosis of most GBM patients remains poor 
and recurrence is almost inevitable with median survival of 
5.0 months.4 Treating recurrent GBM is even more difficult 
than the newly diagnosed cases since the second surgical 
resection is not always feasible and in many cases, the tumor 
develops resistance to radiation and chemotherapy.
GBM is a disease caused by the accumulation of genetic 
mutations resulting in uncontrollable proliferation of cells, 
which are also highly heterogeneous. Recent advances in 
genomics, proteomics, and bioinformatics provide a vast 
amount of information underlying molecular mechanisms 
of GBM initiation and progression, leading to development 
of gene-targeted therapies.5–7 The three critical pathways 
involved in GBM are the RTK/RAS/PI3K pathway, the p53 
pathway, and the CDK/cyclin/CDK inhibitor/RB pathway. 
These have been found to be disrupted in more than 75% 
of GBM samples.8 Considering the complex and compensa-
tory nature of the signaling, therapeutic targeting of a single 
molecule, or even of an entire pathway, is not likely to achieve 
clinically significant or meaningful anticancer effects.
In this context, oncolytic virus-based gene therapy emerges 
as a potentially attractive platform by combining the viral rep-
licative lytic capacity for tumors with additional transfer of 
genes that mediate anticancer effects.9 For GBM therapy, 
herpes simplex virus (HSV), adenovirus, measles, and reo-
virus have been extensively studied and their safety and effi-
cacy have been evaluated in Phase 1 clinical trials.10,11 HSV 
type 1 (HSV1) oncolytic viruses possess several advantages 
for brain tumor treatment, namely, its capacity to accommo-
date several transgenes, its natural neurotropism, its high 
infectivity for and rapid lysis of cancer cells, the relative ease 
of genetic manipulation, and the availability of antiviral drugs 
to prevent unintentional viral spread.12–14 Very attenuated 
oncolytic HSVs (oHSVs) have been well tolerated in Phase I 
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Toxicology of MGH2.1 and Prodrugs
MGH2.1 is a herpes simplex virus type 1 (HSV1) oncolytic virus that expresses two prodrug-activating transgenes: the 
cyclophosphamide (CPA)-activating cytochrome P4502B1 (CYP2B1) and the CPT11-activating secreted human intestinal 
carboxylesterase (shiCE). Toxicology and biodistribution of MGH2.1 in the presence/absence of prodrugs was evaluated 
in mice. MGH2.1 ± prodrugs was cytotoxic to human glioma cells, but not to normal cells. Pharmacokinetically, intracranial 
MGH2.1 did not significantly alter the metabolism of intraperitoneally (i.p.) administered prodrugs in mouse plasma, brain, or 
liver. MGH2.1 did not induce an acute inflammatory reaction. MGH2.1 DNA was detected in brains of mice inoculated with 108 
pfus for up to 60 days. However, only one animal showed evidence of viral gene expression at this time. Expression of virally 
encoded genes was restricted to brain. Intracranial inoculation of MGH2.1 did not induce lethality at 108 pfus in the absence 
of prodrugs and at 106 pfus in the presence of prodrugs. This study provides safety and toxicology data justifying a possible 
clinical trial of intratumoral injection of MGH2.1 with peripheral administration of CPA and/or CPT11 prodrugs in humans with 
malignant gliomas.
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clinical trials for GBM. However, clinically significant efficacy 
remains elusive, likely because the current clinical generation 
of oHSV is attenuated and compromised in immune evasion 
ability and in the degree of replicative cytotoxicity.13,15,16
Newer generations of viral vectors have been developed 
to improve efficacy without compromising safety. MGH2 was 
originally engineered from wild HSV1 virus F strain:17 in addi-
tion to a deletion of the viral UL39 transgene that provides rep-
licative selectivity for cells with p16 tumor suppressor defects18 
and to deletions of both copies of the ICP34.5 neurovirulence 
genes (i.e., thereby rendering it genetically similar to G207, 
an oHSV tested in several clinical trials, refs. 19,20), MGH2 
also contains two transgene transcriptional units encoding two 
different prodrug-activating genes: rat cytochrome P4502B1 
(CYP2B1)21 and secreted human intestinal carboxylester-
ase (shiCE).22,23 CYP2B1 converts cyclophosphamide (CPA) 
into the active anticancer DNA-alkylating metabolite, phos-
phoramide mustard (PM), whereas shiCE converts irinotecan 
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(CPT11) into the active topoisomerase I inhibitor, SN-38. 
MGH2 exhibited significant activity against human glioma 
cells both in vitro and in vivo that was enhanced by the addi-
tion of CPA and CPT11. CPA is an alkylating agent used in 
cancer treatment with dose-dependent biological activity as 
a cytotoxic and immunosuppressive agent at high dose and 
antiangiogenic and immunostimulatory agent at low dose.24  
CYP2B1 encodes hepatic CYP2B1, an extensively studied 
prodrug-activating enzyme, which converts CPA to its antican-
cer metabolite PM.25 PM acts as a DNA cross-linking agent,26 
altering DNA structure, and resulting in apoptotic cell death. 
CPA can also function as an immunomodulator that enhances 
oHSV replication through inhibition of antiviral natural killer cell 
and mononuclear cell responses.27–35 Irinotecan is also widely 
used in cancer treatment and activated by carboxylesterase 
(CE) into SN-38, a potent DNA topoisomerase I inhibitor.36 The 
efficacy of irinotecan has been reported to be enhanced when 
combined with other anticancer drugs in patients with glioma.37 
The human intestinal form of CE expresses a truncated car-
boxyl terminus to enable the extracellular secretion of the drug 
on the surrounding noninfected cells (P. Potter, unpublished 
results). MGH2.1 in combination with CPA/CPT11 exerts 
its anticancer effects through four distinct modes of action: 
(i) immunomodulation by CPA improves oHSV replication; (ii) 
transgene-mediated activation of CPA and CPT11; (iii) direct 
oHSV replication and cytotoxicity; and (iv) bystander effect of 
cytotoxic metabolites released from infected/lysed cells. We 
have previously shown that oncolytic virus-mediated activa-
tion of the prodrugs, CPA and/or CPT11, produced more in 
vitro cytotoxicity against glioma cells and led to significantly 
increased survivorship of mice harboring brain glioma xeno-
grafts, when compared with treatment with prodrugs alone.17 
In order to provide data related to this strategy’s toxicology, 
safety, and biodistribution, we report experiments designed 
to show that mice tolerate the combination of oHSV and two 
prodrugs well. As part of the effort to proceed into clinical tri-
als, MGH2 was genetically modified to MGH2.1 by removing a 
green fluorescent protein (GFP) expression cassette from its 
genome, as described in the Materials and Methods section. 
These data, thus, justify a possible clinical trial of MGH2.1 in 
combination with CPA and CPT11 in patients with malignant 
glioma.
Results
Effects of MGH2.1 with and without CPA/CPT11 toward 
human glioma and normal cells
We first sought to establish the in vitro cytotoxicity of 
MGH2.1, CPA, and CPT11 at various dose levels in human 
astrocytes and three human glioma cell lines (Gli36, U87, 
and U251). MGH2.1 alone reduced the survival of all three 
glioma cell lines in a dose-dependent manner, but not that of 
human astrocytes, even at a multiplicity of infection (MOI) of 
10   (Figure 1a). Each of the two prodrugs, CPA and CPT11, 
also reduced the survival of glioma cell lines but not that of 
human astrocytes (Figure 1b,c, respectively), in spite of their 
“prodrug” status perhaps because of incubation at 39.8 °C, 
when compared to controls. Because there was selective 
glioma cell cytotoxicity from the prodrugs alone at this high 
temperature, we next sought to determine if expression of the 
MGH2.1-encoded transgenes, CYP2B1 and shiCE, respec-
tively converted the prodrugs CPA and CPT11 in glioma 
and normal cells to provide additional cytotoxicity (Figure 
1d). For glioma cells, doses of MGH2.1, CPA, and CPT11 
were selected at MOI of 0.1, 250 µmol/l and 0.05 µmol/l, 
respectively. For human astrocytes, doses of reagents were 
increased to MOI = 10, 1,000 µmol/l of CPA, and 0.2 µmol/l 
of CPT11. In order to study the effect of prodrug conversion 
without the confounding variable of MGH2.1 replicative cyto-
toxicity, the next set of experiments were conducted utilizing 
Figure 1  In vitro cytotoxicity assays. (a) Dose effect of MGH2.1 alone. HA and human glioma cell lines (Gli36, U87, and U251) were treated 
with increasing concentrations of MGH2.1. Three hours after infection with MGH2.1 at 37 °C, cells were washed to remove unattached viral 
particles and fresh medium was added back. Five days later, surviving cells were measured colorimetrically with CytoTox 96 Non-Radioactive 
Cytotoxicity Assay and confirmed numerically with a Coulter counter. Plotted values represent the mean ratio of surviving cells after treatment 
with MGH2.1 versus mock compared with mock, from experiments performed in triplicate and are defined as the fractional cell ratio. Standard 
deviations are indicated by error bars. While MGH2.1 did not show statistically significant cytotoxicity on HA, MGH2.1 at MOI = 1 and 10 
caused significant reduction of cell survival of glioma cell lines (P < 0.0001). (b) Dose effect of CPA alone. Cells were incubated in medium 
containing CPA at 37 °C for 3 hours and then transferred to a 39.8 °C incubator. Four days later, surviving cells were measured. CPA caused 
significant cytotoxicity on Gli36 at 250 µmol/l (P = 0.0041), 500 µmol/l (P = 0.0050), and 1,000 µmol/l (P < 0.0001); U87 at 250 µmol/l (P = 
0.0020), 500 µmol/l (P = 0.0391), and 1,000 µmol/l (P = 0.0084); and U251 at 500 µmol/l (P = 0.0043) and 1,000 µmol/l (P < 0.0001). (c) 
Dose effect of CPT11 alone. Cells were treated similarly to cells treated in b. CPT11 caused significant cytotoxicity to Gli36 at 0.05 µmol/l   
(P = 0.0195), 0.1 µmol/l (P = 0.0355), and 0.2 µmol/l (P = 0.0002); U87 at 0.1 µmol/l (P = 0.0324) and 0.2 µmol/l (P = 0.0054); and U251 at 
0.05 µmol/l (P = 0036), 0.1 µmol/l (P = 0.0005), and 0.2 µmol/l (P < 0.0001). (d) Effect of TS MGH2.1 in combination with CPA and/or CPT11 in 
HA (MOI = 10) and glioma cell lines (MOI = 0.1). Cells were incubated in medium containing CPA at 37 °C for 3 hours and then transferred to 
a 39.8 °C incubator to stop MGH2.1 replication. By stopping viral replication, cytotoxicity mediated by CYP2B1 and shiCE conversion of CPA 
and CPT11, respectively, into their active anticancer metabolites can be assayed without the confounding variable of cytotoxicity mediated by 
the replicating oncolytic virus, as detailed in Aghi et al. (1999).38 Four days later, surviving cells were measured. Compared with no-treatment 
controls, the combination of MGH2.1 and prodrugs caused significant cytotoxicity to Gli36 (P < 0.001), U87 (P = 0.003), and U251 (P < 
0.001), while no effect was observed for HA. (e) Effect of CPA and CPT11 versus TS MGH2.1 + CPA and CPT11 in Gli36 and U251 cells. The 
MOI of MGH2.1 was increased to 1 and the dose of prodrugs was halved compared with that in d, in order to maximize cell infectivity and 
minimize effects of prodrugs alone. (f) Effect of TS MGH2.1 and CPA and/or CPT11 on glioma “stem-like” cells, G97, G68, OG02, and X12. 
(g) Effect of replicative MGH2.1 with or without prodrugs against a panel of normal cells: R. Epi., Hepato., SM, HUVEC, HA, SkM, Fibro., and 
MN cells. Cells were infected with MGH2.1 for 1 hour at 37 °C and then fresh medium containing 1,000 µmol/l CPA and/or CPT11 was added. 
Unlike above experiments, incubation was carried out at 37 °C for the full 5 days, before measuring surviving cells. Statistical analyses were 
conducted by Dunnet’s method to evaluate (a) MGH2.1 dose effect, linear models (analysis of variance) with Bonferroni correction to control for 
type I error to evaluate dose effects of (b) CPA, or (c) CPT11, and Student’s t test was used to evaluate combination effects of (e–g) MGH2.1 
± CPA ± CPT11. *P < 0.05; #P < 0.01. All comparisons are made between the treatment effect and the mock control. CPA, cyclophosphamide; 
Fibro., pulmonary fibroblast; HA, human astrocyte; Hepato., hepatocyte; HUVEC, human umbilical venous endothelial cell; MN, mouse neural 
cells; MOI, multiplicity of infection; R.Epi., renal epithelial cells; SkM, skeletal muscle cells; SM, smooth muscle cells; TS, temperature-shifted.Molecular Therapy—Nucleic Acids
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the temperature shift method,38 where 4 hours after infection 
of glioma cells with MGH2.1, viral replication is stopped by 
raising the temperature from 37 to 39.8 °C, in the presence 
or absence of prodrugs. Five days later, cells were counted. 
In spite of the temperature-mediated viral replicative block, 
the 4-hour replicative infection of MGH2.1 at MOI = 0.1 still 
reduced the survival of the three established glioma cell lines 
compared with control by 20–30% (Figure 1d). The combi-
nation of CPA and CPT11 also reduced the survival of all 
three glioma cells. Finally, the combination of initial infec-
tion with MGH2.1 that was replicatively blocked and of CPA 
and CPT11 significantly reduced survival when compared 
with CPA and CPT11 alone for Gli36 and U251 but not U87 
glioma cells (Figure 1d). In order to minimize unconverted 
prodrug cytotoxicity and to maximize the degree of infectivity 
of cells, we repeated the experiment by reducing the dose 
of prodrugs by half and increasing the dose of MGH2.1 to a 
MOI of 1 in the Gli36 and U251 glioma cells only. The data 
of Figure 1e show that the increased MOI of MGH2.1 also 
increased the relative cytotoxicity in spite of the temperature-
mediated replicative block, when added alone. Again, we 
detected a significant increase (of about 70%) in cytotoxicity 
when replicatively blocked MGH2.1 was combined with both 
prodrugs when compared with prodrugs alone (Figure 1e). 
In agreement with our previously published findings, this pro-
vided evidence that MGH2.1 did lead to additional conver-
sion of the two prodrugs in infected cells.17 We then tested 
the cytotoxicity of MGH2.1 (MOI = 1) ± CPA and/or CPT11 
against five primary glioma cells. While the temperature shift-
mediated replicative block of MGH2.1 infection at MOI = 1 
did not significantly reduce the cell number of primary glioma 
cells other than an approximate 10% decrease in X12, its 
combination with either or both prodrugs significantly reduced 
cell numbers of all glioma cells (P < 0.001) (Figure 1f). We 
next sought to determine if MGH2.1 replication in the pres-
ence or absence of prodrugs was cytotoxic to normal cells. 
These experiments were conducted at 37 °C to allow for viral 
replication. Infection of MGH2.1 at MOI = 10 in the presence 
of the both prodrugs led to a very small reduction in survival 
rates in some (human fibroblasts and skeletal muscle cells) 
but not all human primary normal cells (astrocytes, hepatic, 
human umbilical venous endothelial cell, renal, and smooth 
muscle) and also did not affect mouse neurons (Figure 1g). 
These data thus showed that MGH2.1 in combination with 
prodrugs was well tolerated by normal cells.
Prodrug metabolism
CPA is metabolized by the hepatic cytochrome 450 sys-
tem,25,39–42 whereas CPT11 is metabolized by serum CEs.23,43 
To determine if there were alterations in the normal metabo-
lism of both prodrugs when administered systemically in the 
presence of intracranial MGH2.1, prodrug metabolite levels, 
SN-38 (CPT11 metabolite) and PM (CPA metabolite), were 
assayed in plasma, brain, and liver of Balb/C mice intracranially 
Figure 2  Prodrug metabolite assay. Concentrations of the prodrug, (a) CPA, and its metabolite, (b) PM, and of the prodrug, (c) CPT11, and 
its metabolite, (d) SN-38, were measured in plasma, brain, and liver of mice injected with MGH2.1 or mock in the presence of systemic CPA 
and CPT11. Viable MGH2.1 (1 × 106 pfus) or heat-inactivated mock was inoculated into mouse brains, stereotactically. The next day, 2 mg of 
CPA and 2 mg of CPT11 was injected intraperitoneally, and blood, brain, and liver were collected at 10 minutes and 30 minutes, 1, 2, 4 and 6 
hours after dosing. The concentrations of analytes are shown as ng/ml for the plasma samples and ng/g for brain or liver samples. Each plot 
represents the average of duplicate samples and standard deviations were indicated by error bars. Student’s t test was used for comparison 
between viable MGH2.1 and mock groups. CPA, cyclophosphamide; PM, phosphoramide mustard.
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injected with 106 pfus of MGH2.1 or mock (heat-inactivated 
MGH2.1). The day after virus injection, both CPA and CPT11 
were administered intraperitoneally (i.p.) at a dose of 2 mg in 
100 µl phosphate-buffered saline (PBS). Animals were killed 
at 10 minutes, 30 minutes, 1, 2, 4, and 6 hours after prodrug 
injection, and blood, brain, and liver were immediately har-
vested and processed for measurements of metabolites by 
mass spectrometry (detailed procedure in Supplementary 
Materials and Methods). As expected, there were higher 
concentrations of both prodrugs and their metabolites in liver 
compared with plasma and brain   (Figure 2). No significant 
difference in the levels of CPA, CPT11, PM, and SN-38 in 
plasma, brain, and livers, except for SN-38 levels in plasma 
(P = 0.0213, two-tailed paired t test) was observed between 
MGH2.1 and mock infection groups. Taken together, these 
results indicated that intracranial injection of MGH2.1 did 
not significantly alter the metabolism of systemic CPA and 
CPT11.
Detection of viral DNA and transcripts in brain and 
 trigeminal  ganglia
We then sought to determine presence of viral DNA and 
transcripts in brains and trigeminal ganglia (TG). Seven days 
after virus inoculation at a dose of 5  ×  107 pfus, viral DNA 
polymerase was detected in all brain samples regardless of 
prodrugs. Interestingly, viral genomic DNA was also detected 
in TG in two of three animals treated with MGH2.1 + CPA, 
one of three animals treated with MGH2.1 + CPT11, and 
none of the animals treated with MGH2.1 alone (Figure 3a). 
We then analyzed for presence of MGH2.1 at 60 days. After 
injection of MGH2.1 (1  ×  107  or  1 × 108 pfus), viral DNA poly-
merase was still present in five out of five brains inoculated 
with  1 × 108 pfus of MGH2.1 and in three out of five brains 
inoculated with 1 × 107 pfus of MGH2.1 (Figure 3b). However, 
no viral DNA was detected in TG. Expression of viral latency-
associated transcript (LAT) and of the two encoded trans-
genes (rat CYP2B1 and human shiCE) was evaluated by 
reverse transcription-PCR (RT-PCR) of brain and TG obtained 
from the mice, 60 days after MGH2.1 intracranial injection. 
Expression of LAT was detected in none of the five brains 
and one of five TGs from the lower MGH2.1 dose group, and 
one of five brains and two of five TG samples from the higher 
dose group (Figure 3c). The transgene shiCE transcript was 
expressed in one of the TGs that also expressed LAT in the 
higher dose group. However, no CYP2B1 transgene expres-
sion was observed in any group.
Systemic biodistribution of virally encoded transcripts 
and viral LAT after MGH2.1 intracerebral injection
We next proceeded to assay for the presence of MGH2.1-
encoded transcripts in multiple organs after MGH2.1 inoc-
ulation in mice brains. Brains, liver, lung, heart, intestines, 
testis, spleen, lymph nodes, and TG of Balb/C mice intra-
cranially injected with MGH2.1 (5  ×  107 pfus) in the pres-
ence or absence of systemic prodrugs were harvested and 
RT-PCR for CYP2B1,  shiCE, and LAT was carried out, 7 
days after MGH2.1 injection (Figure 4). Since CYP2B1 
expression is under control of the HSV1 IE 4/5 promoter 
Figure 3  Detection of viral genomic DNA and LATs. (a) MGH2.1 (5 × 107 pfus) ± CPA (intraperitoneally (i.p.) at 1, 3, 5, and 7 days) or 
CPT11 (i.p. at 1 day) was intracerebrally injected in mice and viral genomic DNA was isolated from brain and TG 7 days after virus inoculation. 
(b) MGH2.1 (107 and 108 pfus) was intracerebrally injected in mice and viral genomic DNA was isolated from brain and TG 60 days after 
virus inoculation. PCR for viral DNA pol was carried out by 35-cycle amplification, and amplified products were separated by agarose gel 
electrophoresis. Mouse β-actin was used as an internal control for genomic DNA. (c) Expression of transgenes (rat CYP2B1 and human 
shiCE) and LAT were analyzed by reverse transcription-PCR 60 days after intracerebral inoculation of MGH2.1 or PBS. Mouse GAPDH was 
used as an internal control for mRNA. CPA, cyclophosphamide; CYP2B1, cytochrome P4502B1; LAT, latency-associated transcript; PBS, 
phosphate-buffered saline; pol, polymerase; shiCE, secreted human intestinal carboxylesterase; TG, trigeminal ganglia.
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(Supplementary Figure S1a), its expression would indicate 
persistent viral infection in a tissue, unlike LAT which may indi-
cate only latent virus. RNA extracted from U251 cells infected 
with MGH2.1 or wild-type F strained was utilized as positive 
and negative control, respectively. Distribution of transgenes 
and LAT was essentially restricted to the brain regardless of 
administration of CPA and/or CPT11. One out of three mice 
injected with MGH2.1 in the presence of CPA showed LAT 
expression in the TG, suggestive of possible viral latency or 
distribution due to immunomodulating effect of CPA.
Serum cytokine profile in animals after intracranial 
  injection with MGH2.1
We investigated whether there was a change in serum cyto-
kines associated with acute inflammatory responses after 
intracranial injection with MGH2.1. Serum was prepared from 
Balb/C mice 3, 7, 14, and 60 days after intracranial injection 
of  5 × 107 pfus of MGH2.1. Serum from mice without virus 
injection was utilized as a negative control. There was a small 
increase in interleukin-6 (IL-6) after MGH2.1 intracranial inoc-
ulation that remained elevated for the duration of the experi-
ment. There were no changes in tumor necrosis factor-α 
(TNF-α), interferon-α (IFN-α), IFN-β, or IFN-γ before or after 
MGH2.1 intracranial injection (Table 1). This suggested that 
intracerebral MGH2.1 was associated with minor increases 
in serum IL-6 without evidence of clinical significance.
Lethality of MGH2.1 with and without prodrugs after 
intracranial injection
To further determine if there was evidence of severe clini-
cal toxicity, a survival study was conducted. Intracerebral 
toxicity of MGH2.1 was compared with that of wild-type F 
strain in young (aged 8 weeks) Balb/C mice. Different doses 
of viruses (5 µl volume) were stereotactically injected into 
the white matter of the right hemisphere of mice. The body 
weight of animals was recorded weekly and the survival was 
followed for 9 weeks. MGH2.1 did not cause lethality at the 
highest dose tested (108 pfus), whereas lethality was evident 
with F strain at a dose as low as 104 pfus (Table 2). In fact, 
the calculated LD50 for F strain was 6.8  ×  103 pfus, in agree-
ment with published studies. There was some initial weight 
loss in mice inoculated with MGH2.1 at the higher inoculated 
doses, but weight returned to baseline within a few weeks 
after viral inoculation with weight gain ensuing thereafter 
Figure 4  Biodistribution of intracerebrally injected MGH2.1. MGH2.1 (5 × 107 pfus) ± CPA (intraperitoneally (i.p.) at 1, 3, 5, and 7 days) 
or CPT11 (i.p. at 1 day) was intracerebrally injected in mice and viral mRNA was isolated after 7 days. Reverse transcription-PCR for the two 
encoded transgenes (rat CYP2B1 and human shiCE), for the viral LAT gene and, for mouse GAPDH as a control was carried out in brains, 
liver, lung, heart, intestines, testis, spleen, lymph nodes, and TG. RNA from U251 infected with MGH2.1 or wild-type F strain was used as 
control. RNA after reverse-transcription was amplified for 35 cycles, and amplified products were separated by agarose gel electrophoresis. 
CPA, cyclophosphamide; CYP2B1, cytochrome P4502B1; LAT, latency-associated transcript; LN, lymph node; shiCE, secreted human 
intestinal carboxylesterase; TG, trigeminal ganglia.
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Table 1  Serum chemokine levels in Balb/C after MGH2.1 intracerebral inoculation
Reliable range (pg/ml) Day 0 Day 3 Day 7 Day 14 Day 60
TNF-α 120–3,850 87.44 (±201.39) 94.80 (±87.39) N.D. N.D. 100.12 (±162.76)
IL-6 0–250 2.64 (±1.47) 13.52 (±5.33) 7.51 (±1.48) 4.82 (±8.04) 15.93 (±5.15)
IFN-α 30–500 18.32 (±1.28) 25.37 (±5.77) 34.34 (±18.61) 18.15 (±2.22) 28.47 (±25.27)
IFN-β 15–1000 N.D. N.D. N.D. N.D. N.D.
IFN-γ 15–250 N.D. N.D. N.D. N.D. N.D.
IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
Serum cytokines associated with acute inflammatory was analyzed by ELISA before and 3, 7, 14, and 60 days after MGH2.1 (5 × 107 pfus) inoculation into Balb/C 
mouse brain. Reliable ranges (pg/ml) were defined by standard curve (P < 0.05).
N.D. indicates values below zero or below minimum reliable values.www.moleculartherapy.org/mtna
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(Supplementary Figure S2a). In fact, by the end of 9 weeks, 
there were no statistically significant differences in body 
weights between mice injected with 1  ×  108 pfus of MGH2.1 
versus those injected with mock.
Next, we evaluate the lethality of MGH2.1 in combination 
with prodrugs in young (aged 8 weeks) Balb/C mice (Table 3). 
Virus was injected intracranially at day 0, CPT11 (0.1 mg/kg) 
was injected i.p. at day 1, and/or CPA (0.1 mg/kg) was injected 
i.p. at days 1, 3, 5, and 7. The combination of prodrugs in the 
absence of MGH2.1 was not lethal and did not cause signifi-
cant body weight reduction other than the first week (Supple-
mentary Figure S2b). While CPA in combination with 5 × 107 
pfus of MGH2.1 was not lethal, CPT11 with MGH2.1 led to 
the death of one out of 18 mice. The combination of virus 
at  5 × 107 pfus and both prodrugs also caused death in one 
out of six mice. MGH2.1 was still lethal at the dose of 5 × 106 
pfus when combined with both prodrugs. However, all of 19 
mice injected with MGH2.1 at a dose of 1 × 106 pfus in com-
bination with CPA and CPT11 survived through the course 
of the experiment. The maximum tolerated dose for injection 
in a brain without tumor of MGH2.1 + CPA was not achieved 
(i.e., above 5 × 107 pfus) and for MGH2.1 + CPT11, it was 106 
pfus (Table 3). The LD50 of MGH2.1 in combination with CPA 
was thus not calculable, that in combination with CPT11 was 
1.24 × 1041 pfus, while that in combination with both prodrugs 
was 3.53 × 108 pfus.
Discussion
We have previously shown that oncolytic virus-mediated acti-
vation of the prodrugs, CPA and/or CPT11, produced more in 
vitro cytotoxicity against glioma cells and led to significantly 
increased survivorship of mice harboring brain glioma xeno-
grafts, when compared with treatment with prodrugs alone.17 
In this report, we show that the combination of MGH2.1, CPA, 
and CPT11 was cytotoxic to human glioma cells, including 
glioma “stem-like” cells and did not significantly affect the 
viability of a panel of normal human and mouse cells. Impor-
tantly, the intracerebral administration of MGH2.1, express-
ing the two prodrug-activating transgenes, also did not alter 
the endogenous metabolism of CPA and CPT11. MGH2.1 
DNA and transcripts were largely confined to the brain after 
intracranial injection and did not end up in organs outside the 
central nervous system even in the presence of CPA and/
or CPT11. MGH2.1 intracerebral injection alone was not 
associated with lethality at doses up to 108 pfus, while the 
combination of MGH2.1 (intracerebral) and systemic CPA + 
CPT11 was not associated with lethality at a dose of 106 pfus. 
Therefore, these studies establish an animal toxicology and 
biodistribution set of findings that can be useful for further 
design of a clinical trial of MGH2.1 with and without CPA and/
or CPT11 in humans with malignant glioma.
MGH2.1 provides multimodal therapeutics in the context of 
a single bioagent for a cancer, such as glioblastoma, where 
multiple genes are mutated and multiple signaling pathways 
are deregulated. Therefore, the multiple modes of tumor 
killing may potentially circumvent the tumor cell’s ability to 
escape from anyone single treatment. In fact, tumor cell toxic-
ity arises from: (i) the direct cytotoxic action of MGH2.1 viral 
infection and lysis of tumors; (ii) the alkylation of tumor cell 
DNA by CPA’s activated metabolites that can also diffuse 
out and kill other tumor cells, even if MGH2.1 did not infect 
them;44 (iii) the inhibition of tumor cell topoisomerase I activ-
ity by CPT11’s activated metabolite that can also kill other 
noninfected tumor cells, by diffusion of the metabolite or of 
the prodrug-activating enzyme22; and (iv) the enhancement 
of MGH2.1 replication by the immunomodulatory effects of 
CPA.35 Results from the in vitro cytotoxicity studies show 
that MGH2.1, in combination with prodrugs, was more toxic 
to human glioma cell lines and primary glioma cells than 
MGH2.1 alone, providing evidence for the effectiveness of 
multiple mechanisms of tumor cell kill. It should be noted that 
the experiments shown in Figure 1d–f measure cytotoxicity 
mediated by only a 4-hour infection and replicative cycle of 
MGH2.1 due to the 37 to 39.8 °C temperature shift38 com-
bined with virus-encoded transgene–mediated conversion 
of CPA and/or CPT11, whereas the experiments shown in 
Figure 1g measure cytotoxicity mediated by the fully replica-
tive oncolytic virus with and without prodrugs. In this context, 
when multiple mechanisms of tumor cell toxicity are opera-
tive, one concern is that they can also lead to increased tox-
icity against normal cells. At least in vitro, this was not the 
Table 2  Lethality of MGH2.1 and wild-type strain F after intracerebral 
  injection in Balb/C mice
Strain Dose (pfu) Survival/total Survival (%)
MGH2.1 1 × 106 10/10 100
1 × 107 5/5 100
5 × 107 20/20 100
1 × 108 5/5 100
Mock 5 × 107 11/11 100
F 1 × 103 5/5 100
1 × 104 2/5  40
1 × 105 3/15  20
PBS NA 9/9 100
NA, not available; PBS, phosphate-buffered saline. 
Eight-week-old Balb/C mice were intracerebrally inoculated with virus, and 
survival was followed for 9 weeks.
Table 3  Lethality of MGH2.1 after intracerebral injection in combination with 
systemic prodrugs in Balb/C mice
MGH2.1 (pfu) CPA (mg/kg) CPT11 (mg/kg) Survival/total Survival (%)
5E+7 – – 20/20 100
– 0.1 0.1 20/20 100
5E+7 0.1 – 6/6 100
5E+7 – 0.1 17/18  94
5E+7 0.1 0.1 5/6  83
5E+6 0.1 0.1 9/10  90
1E+6 0.1 – 5/5 100
1E+6 – 0.1 5/5 100
1E+6 0.1 0.1 19/19 100
Mock 0.1 0.1 5/5 100
CPA, cyclophosphamide; i.p., intraperitoneal.
Eight-week-old Balb/C mice were intracerebrally inoculated with virus at day 
0. CPT11 (0.1 mg/kg) was injected i.p. at day 1, and/or CPA (0.1 mg/kg) was 
injected i.p. at days 1, 3, 5, and 7. The survival was followed for 9 weeks.Molecular Therapy—Nucleic Acids
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case: even combined at their highest tested dose (MOI = 10 
for MGH2.1, 1000 µmol/l for CPA, and 0.2 µmol/l for CPT11), 
there was no significant effect on human astrocyte viability or 
on the viability of a panel of normal cells. Therefore, in vitro 
the combination of MGH2.1 and its two prodrugs increases 
glioma cell cytotoxicity without affecting the viability of normal 
cells.
Both CPA and CPT11 are metabolized by endogenous 
enzymes. CPA is primarily metabolized by the hepatic cyto-
chrome P450 system with rat CYP2B1 being the most active 
catalytic isozyme for this reaction.25 CPA is first metabolized 
into the unstable intermediate 4-hydroxy CPA which sponta-
neously degrades into PM and acrolein.39 PM is the active 
anticancer agent that alkylates DNA and, thus, leads to DNA 
damage and cell death.40 CPT11 is metabolized by serum 
CEs into its active anticancer metabolite, SN-38, that inhibits 
topoisomerase I, thus leading to DNA damage.36 In addition, 
a number of intracellular CEs can also catalyze this reac-
tion and shiCE is such an isozyme.22,23,43 We had previously 
shown that the active metabolites of CPA (4-hydroxy CPA and 
its metabolites)45 and that of CPT11 (SN-38) were cytotoxic 
to glioma cells.17 In addition, expression of CE and CYP2B1 
in the context of the oHSV1, MGH2 (i.e., MGH2.1 with a GFP 
transgene) was highly effective against intracranial gliomas 
in mice when combined with systemic CPA and CPT11.17 The 
rationale for this is that, in spite of endogenous bioconver-
sion of the two prodrugs, there was still sufficient prodrug not 
being converted that could be activated locally in tumor by 
MGH2. Evidence for this mechanism was shown previously 
where local conversion of CPA by a replicating HSV express-
ing CYP2B1 was shown.45 However, one concern may be 
that the local intratumoral bioconversion of the two prodrugs 
could alter or change systemic endogenous pharmacokinet-
ics. The data in this paper show that intracranial inoculation of 
MGH2.1 or mock followed by i.p. injection of CPA and CPT11 
into immunocompetent Balb/C mice did not alter the pharma-
cokinetics of prodrugs and their metabolites in brain, serum, 
and liver. This suggests that MGH2.1 replication/infection 
is minimal in naive brains and the observed expression of 
shiCE and CYP2B1 (Figure 4) would not be meaningful 
enough to alter the endogenous metabolism of the two pro-
drugs. Although the same amount of CPA and CPT11 were 
injected, the concentrations of CPA and its metabolite PM 
were higher than those of CPT11 and SN-38 by an order 
of magnitude in brain, which likely reflect the differences in 
regard to half-life of the prodrugs and metabolites, ability of 
prodrugs to cross brain–blood barrier, and enzyme activity. 
Therefore, the endogenous kinetics of prodrug metabolism 
were not altered by the injection of virus in brains.
In terms of immune reactions, intracranial injection of 
MGH2.1 in immunocompetent Balb/C did not elicit induc-
tion of serum cytokines (TNF-α, IFN-α, IFN-β, or IFN-γ), and 
only a marginal increase of IL-6 was detected at the vari-
ous time points. We do anticipate that MGH2.1 administra-
tion may induce anticancer immune response through viral 
replication followed by cell lysis in tumor-bearing animals. 
Modulating host immunity in viral cancer therapy is tricky. 
Antiviral immune response should be suppressed until infec-
tion and replication is established in target tumor cells. At this 
juncture, antitumor immune response should be induced by 
viral molecules produced upon successful viral replication, 
such as dsRNA, and/or processed antigens specific to virally 
infected cells. CPA, an alkylating agent widely used in vari-
ous cancer treatments, has also immunosuppressive effect 
and has been shown to improve replication of oHSV in tumor 
cells both in vitro and in vivo.9,27–29,31,33–35,46,47 We observed that 
there was an expected CPA effect on enhancement of in vitro 
cytotoxicity of MGH2.1 in the present study, as well.
Seven days after intracranial virus injection, viral genomic 
DNA was observed in all brain samples regardless of pro-
drug administration. In some of prodrug-treated animals, TG 
also exhibited viral DNA (Figure 3a). This shows that pro-
drugs (likely CPA) may enhance the ability of virus to travel 
to TG, where the virus likes to harbor in a latent state. By 60 
days after virus injection without prodrug treatment, brains, 
but not TG, still harbored viral genomic DNA (Figure 3b). 
HSV1 is thought to establish latency in TG in both human and 
mouse. Intracerebrally injected HSV was observed to spread 
via retrograde transport to neurons.48–50 RNA and DNA of LAT 
and viral genes were detected in TG of mice latently infected 
HSV1 at 60 days after infection, although there was no con-
clusive data regarding their replication.51 Systemic dissemi-
nation of intracranially administered MGH2.1 was assayed 
in naive immunocompetent Balb/C mice by Q-PCR. Various 
organs were harvested from animals killed 7 days after virus 
injection. All brain samples expressed transgenes and LAT 
genes regardless of prodrug treatment. Other than brain tis-
sue, only one TG harvested from CPA-treated animal exhib-
ited a LAT transcript. Significantly, there was no evidence of 
viral gene expression in other organs, even in CPA-treated 
animals. The lack of transcript expression in organs other 
than the brain (and TG) and the lack of the CYP2B1 tran-
script that is under control of the HSV IE4/5 promoter in the 
brain at 60 days (Figure 3c) argues that MGH2.1 transcripts 
would be unlikely to be found in organs such as liver at 60 
days. The lack of oHSV dissemination in the presence of CPA 
is consistent with a previous result that pretreatment of CPA 
did not cause systemic distribution of oHSV1.32,33,46,52 In these 
studies, we did not observe viral gene expression even in 
CPA-treated TG. However, samples were harvested only 12 
hours after virus injection into the intracranial tumor mass, 
suggesting that time may have been too short for the virus to 
travel to TG. Taken together, our study along with previously 
cited reports confirms that oHSV injected in brains of mice 
remains localized to the central nervous system even in the 
presence of prodrugs that are activated by the oHSV.
The primary objective of this study was to show the safety 
profile of MGH2.1 with/without its prodrugs upon intrace-
rebral injection. Previously, we have shown its efficacy in 
animal models of glioma.17 The LD50 for MGH2.1 in combina-
tion with CPA was not reached, and the LD50 for the virus in 
combination with CPT11 was calculated as 1.24  ×  1041 pfus, 
which is not achievable. MGH2.1 intracerebral administration 
by itself was not lethal to mice at the highest tested dose (108 
pfus), but we did establish an LD50 when it was combined with 
systemic administration with prodrugs at a dose of 3.53 × 108 
pfus. However, we were able to find a dose (106 pfus) that 
was not associated with animal death. In our previously pub-
lished study,17 this dose was effective in an animal model 
of glioma and, thus 106 pfus is the No Observed Adverse www.moleculartherapy.org/mtna
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Event Level dose in mice. This, thus, provides a starting dose 
in an eventual Phase I clinical trial for human subjects with 
malignant gliomas taking into account differences in brain 
weight. There was some dose-dependent weight loss in mice 
intracranially injected with MGH2.1 at the highest dose and 
systemic prodrugs exacerbated this adverse effect, but this 
was a transient effect with animal weight gain returning to the 
original level by a few weeks after surgery. Since the PBS-
injected control group also showed some weight loss, albeit 
to a lesser degree, a portion of this adverse effect can be 
attributed to the anesthesia and surgery.
In summary, these studies provide feasibility data related 
to the toxicology and biodistribution of this novel oHSV in 
combination with its prodrugs in preparation for an eventual 
clinical trial.
Materials and methods
Engineering of MGH2.1. MGH1 is a double-mutant oHSV1 
derived from wild-type F strain containing deletions of both 
copies of ICP34.5 and an insertion in UL39.53 To enhance 
its anticancer therapeutic efficacy, two transgene cassettes 
encoding the prodrug-activating enzymes, rat CYP2B1 
and shiCE, were integrated into MGH1 and designated 
as MGH2.17 CYP2B1 and shiCE convert CPA and irinote-
can (CPT11) into their active metabolites, PM and SN-38, 
respectively. For potential clinical trials, the GFP transgene 
cassette was removed from the MGH2 sequence due to 
its possible immunogenicity (Supplementary Figure S1a). 
Details of the engineering are described in Supplementary 
Materials and Methods. This new oHSV was designated 
as MGH2.1 and three different isolates (1-1-5, s1-2-6, and 
1-2-8) were initially plaque-purified. Of the three MGH2.1 
isolates, 1-2-6 was selected because it showed the highest 
CE activity, the retention of the transgene cassettes, and 
the deletion of the GFP expression cassette. To confirm the 
structural stability of transgenes in its genome, MGH2.1 iso-
late, 1-2-6, was plaque-purified on Master Cell Bank cells 
B7 and N23 (obtained from William B Goins, University of 
Pittsburgh, Pittsburgh, PA) for 20 passages, viral DNA was 
extracted every five passages, and gross genomic structure 
was verified by Southern blot analysis by following published 
procedures17,54 (Supplementary Figure S1b). CYP2B1 and 
shiCE sequences were excised from the transfer plasmid pT-
oriS-IE4/5-CMV-hiCEC and used as probes. A parental strain 
rHSVQ1 (rH) which lacks the transgenes CYP2B1 and shiCE 
was used as a negative control. A single band of 4.8 kb was 
detected in each viral DNA sample of MGH2.1 digested with 
HindIII by using the shiCE fragment as a probe. The CYP2B1 
probe detected 1.4 and 2.2  kb fragments in the samples 
digested with HindIII and with SacII and BglII, respectively. 
The lack of detection of hybridizing fragments for DNA iso-
lated after five passages on N23 was likely due to technical 
issues since later passages showed hybridizations.
In vitro bioequivalence studies were conducted to show 
that MGH2.1 retained secreted intestinal CE activity and 
tumor cell oncolysis to the same magnitude as MGH2 (Sup-
plementary Figure S3). CE activity and production rate of 
its metabolite SN-38 was measured in cultured media and 
cell lysate prepared from Vero cells infected with the virus 
stocks.17 CE activity was higher in cell extracts than medium 
in all samples, which was consistent with production rate of 
SN-38 (Supplementary Figure S3a,b). CYP2B1 function 
was confirmed in terms of cytotoxicity of MGH2.1 in the pres-
ence of CPA (Supplementary Figure S3c). Taken together, 
the newly generated MGH2.1 was confirmed to sustain onco-
lytic activity through prodrug conversion activity comparative 
to its parent strain, MGH2.
Cell culture. Vero cells and human glioma cell lines (U251, 
Gli36, and U87) were cultured in Dulbecco’s modified Eagle’s 
medium (Invitrogen, Carlsbad, CA) supplemented with 2 
or 10% heat-inactivated fetal bovine serum (Invitrogen), 
100 U/ml of penicillin (Invitrogen), and 10 mg/ml of streptomy-
cin (Invitrogen). Primary human glioma cells (G35, G68, G97, 
OG02, and X12) were cultured as spheres under conditions 
to enrich for the glioma “stem-like” cell subpopulation in brain 
tumor stem cell medium consisting of Neurobasal medium 
(Invitrogen) supplemented with GlutaMAX (Invitrogen), B27 
supplements (Invitrogen), 20  ng/ml of human recombinant 
basic FGF (Peprotech, Rocky Hill, NJ), and 20 ng/ml of human 
recombinant EGF (Peprotech). The day before infection, pri-
mary glioma sphere cells were trypsinized and seeded onto 
plates coated with poly-d-lysine (Invitrogen) containing brain 
tumor stem cell medium with reduced concentration of fibro-
blast growth factor and epidermal growth factor (5  ng/ml for 
each) to form monolayers. Primary human cells (astrocyte, 
pulmonary fibroblast, hepatocyte, renal epithelial cells, skel-
etal muscle cells, smooth muscle cells, and human umbili-
cal venous endothelial cell: umbilical vein smooth muscle 
cells) and mouse neural cells were purchased from ScienCell 
Research Laboratories (Carlsbad, CA), and cultured in the 
corresponding medium following the manufacturer’s instruc-
tions. The primary normal cells used in this study were pas-
saged no more than five times, and the aliquots were stored 
in Bambanker serum-free cell freezing medium (Wako Chem-
icals USA, Richmond, VA) at – 80 °C until use. All cells were 
grown at 37 °C in an atmosphere containing 5% CO2.
In vitro virus cytotoxicity assay. Cytotoxicity was evaluated 
and reported as the fraction of cells surviving after onco-
lytic virus infection compared with those treated with vehicle 
(fractional cell ratio). The day before infection, 5  ×  103 cells 
were plated onto 96-well plates in medium prepared follow-
ing manufacturer’s instructions for normal primary cells, brain 
tumor stem cell medium for primary glioma cells or Dulbec-
co’s modified Eagle’s medium supplemented with 2% fetal 
bovine serum for glioma cell lines and allowed to adhere. 
The medium for normal cells was changed to basal medium 
a few hours after cell preparation. The following day, viruses 
were added at various MOIs, as indicated in figure legends. 
MGH2.1, inactivated with ultraviolet radiation, was used as 
a mock control. One hour after infection, cells were washed 
with glycine saline solution (10 mmol/l glycine, 137 mmol/l 
NaCl, 24.1 mmol/l KCl, 0.49 mmol/l MgCl2, and 0.68 mmol/l 
CaCl2, pH 3) followed by PBS to remove unattached viruses 
and fresh medium was then added. Cells were incubated at 
37 °C in an atmosphere containing 5% CO2. Five days after 
infection, virus cytotoxicity was assayed as the amount of Molecular Therapy—Nucleic Acids
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lactase dehydrogenase released upon cell lysis with Cyto-
Tox96 Non-Radioactive Cytotoxicity Assay kit (Promega, 
Madison, WI). For prodrug functional assays, cells were pre-
pared in the same manner as described above. After 1-hour 
incubation in viral solution at 37 °C, fresh medium contain-
ing CPT11 (APP Pharmaceuticals, Schaumburg, IL) and/or 
CPA (Baxter, Deerfield, IL) at indicated concentrations was 
added. Viral replication was then stopped 3 hours later by 
transferring the plates to a 39.8 °C incubator.38 Cytotoxicity 
was measured 4 days later with CytoTox96 Non-Radioac-
tive Cytotoxicity Assay kit. For some cell lines, cytotoxicity 
was measured by enumeration through a Coulter counter 
(Beckman Coulter, Indianapolis, IN). The day before infec-
tion,  5 × 104 cells were seeded onto 12-well plates. Infec-
tion, drug treatment and incubation were performed in the 
same manner as described above. Cells were incubated for 
5 days for dose–response assays and 4 days for prodrug 
functional assays and surviving cells were counted with a 
Coulter counter.
Animal studies. All animal studies were performed in accor-
dance with guidelines issued by The Ohio State University 
Institutional Animal Care and Use Committee, utilizing an 
approved animal protocol. Viral inoculation and care of ani-
mals harboring virus were conducted in approved BL2 labo-
ratory rooms. BALB/c mice were obtained from Charles River 
Laboratories (Wilmington, MA) or the National Cancer Insti-
tute (Frederick, MD). For neurotoxicity experiments, 8-week-
old mice were anesthetized by i.p. administration of ketamine 
(100  mg/kg) and xylazine (20  mg/kg). Oncolytic virus was 
then stereotactically injected into the right frontal lobe of brain 
(2 mm lateral and 1 mm anterior to the bregma at a depth of 
3  mm). PBS and ultraviolet-radiated MGH2.1 were used as 
negative and mock control, respectively. The survival time for 
each group was monitored for 60 days after virus injection 
and body weights were measured weekly. CPA (2 mg in 100 
µl PBS) was administered i.p. at 1, 3, 5, and 7 days after virus 
injection, and CPT11 (2 mg in 100 µl PBS) was injected i.p. 1 
day after virus injection.
Metabolite assays. CPA, CPT11, and their active metabo-
lites, PM and SN-38, were measured with the API-3000 triple 
quadrupole mass spectrometer (ABSciex, Framingham, MA) 
in mouse plasma, brain, and liver tissue. Thirty-six Balb/C 
mice were divided into two groups which were injected intra-
cranially with either mock or 106 pfus of MGH2.1. The next 
day, mice were treated with i.p. injections of CPA (2  mg) 
and/or CPT11 (2  mg). Blood, brain, and liver tissues were 
collected 10 minutes and 30 minutes, 1, 2, 4 and 6 hours 
after drug administration. Blood was collected into heparin 
tubes placed on ice, followed by 10 minutes centrifugation 
(6,000 rpm) at 4 °C. A 200-µl plasma aliquot was transferred 
into an Eppendorf tube with 20 µl of 2 mol/l semicarbazide in 
50 mmol/l potassium phosphate buffer (pH 7.4) and frozen in 
dry ice. Two-hundred milligrams of mouse brain or liver was 
transferred to an Eppendorf tube with 500 µl PBS and 50 µl of 
2 mol/l semicarbazide solution, then homogenized on ice (15 
seconds with a 10-second stop, repeat three times). After 10 
minutes centrifugation (6,000  rpm) at 4 °C, the supernatant 
was transferred to a new Eppendorf tube and frozen in dry 
ice. All samples were stored in −80 °C before analysis. Refer 
to  Supplementary Materials and Methods for detailed 
descriptions of measurement conditions.
PCR and RT-PCR. Brain and organs were harvested from 
animals euthanized at 7 or 60 days after virus inoculation at 
the dose of 5 × 107 pfus (7 days) and 107 or 108 pfus (60 days). 
CPA or CPT11 was injected i.p. at 1, 3, 5, and 7 days (CPA) or 
1 day (CPT11) after virus inoculation. A small piece of tissue 
excised from each organ was immediately placed into RNA 
later tissue storage reagent (QIAGEN, Germantown, MD) 
and stored at 4 °C until use, for a period up to 4 weeks. Viral 
genomic DNA was extracted from the tissues using QIAamp 
DNA Mini Kit (QIAGEN) following the manufacturer’s proto-
col. Total mRNA extraction and first-strand cDNA synthesis 
was conducted using OneStep RT-PCR system (QIAGEN) 
following the manufacturer’s protocol. Primer sequences and 
annealing temperatures are listed in Supplementary Table 
S1. The cDNA products of the reverse transcription reac-
tion were denatured at 95 °C for 15 minutes followed by a 
35-cycle PCR reaction (94 °C for 30 seconds, 56 °C or 63 °C 
for 30 seconds, and 72 °C for 2 minutes). PCR products were 
separated by agarose gel electrophoresis to confirm the size 
of products.
ELISA assay. Blood was collected from three Balb/C mice 
per each time point before and 3, 7, 14 and 60 days after 
MGH2.1  (5 × 107 pfus) inoculation into Balb/C mouse brain. 
Serum was separated by brief centrifugation and used for 
ELISA assays to quantify the concentration of TNF-α (Hycult 
Biotechnology, Uden, Netherlands), IL-6 (Cell Science, Can-
ton, MA), IFN-α (Cell Science), IFN-β (Cell Science), and 
IFN-γ (Cell Science), following manufacturer’s instructions.
Statistical analyses. For MGH2.1 dose effect analyses, a 
square root transformation was used to stabilize the vari-
ances. Dunnet’s method was used to adjust for multiple com-
parisons. For dose effect of CPA or CPT11, linear models 
(analysis of variance) were used to compare cytotoxicity 
among groups and days. Bonferroni was used to control for 
type I error. For primary glioma cells and normal cells, t test 
(one-tailed, unequal variance) was performed.
Supplementary material
Figure S1.  Engineering of MGH2.1.
Figure S2. Effect of intracerebrally injected MGH2.1 ± CPA 
and ±CPT11 on body weights of Balb/C mice.
Figure S3.  In vitro functional assays of transgenes (shiCE 
and CYP2B1) in MGH2.1.
Table S1. List of primers utilized in study. 
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